Migraine
Conditions
Interventions
Rizatriptan benzoate 10mg per dose at onset of acute migraine seizures Sodium loxoprofen 60mg per dose as anhydrate, orally twice a day Perampanel hydrate 2mg per dose, once a daily at bedtime
Sponsors
Tokyo Women's Medical University
Faculty of Pharmaceutical Science, Teikyo Heisei University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Target subjects should be met the following inclusion criteria: 1) Subjects aged 20 or over when getting their informed consent 2) Subjects diagnosed as migraine by the ICHD-III (beta) 3) Subjects experiencing use of triptan agents for at least 3 months or over 4) Subjects experiencing use of either non-steroid inflammatory drugs (e.g. Sodium loxoprofen) or anti-epileptic drugs (e.g. sodium valproate, perampanel hydrate) for at least 3 month or over 5) Subjects suffering from seizures once a month or over in the past year 6) Self-informed consent possible
Exclusion criteria
Exclusion criteria: Exclusion criteria are: 1) Subjects diagnosed secondary headache 2) Subjects judged to be inappropriate as a study subject by the key investigator or sub-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean of time to relieve seizures | — |
Countries
Japan
Contacts
Public ContactToshihiko Shimizu
Tokyo Women's Medical University Neurosurgery
Outcome results
None listed